BioStem Technologies, Inc. Established

Repackaging and Reformulation Facilities Built Out

Addition of Industry Experts and Key Business Advisors to Oversee Growth

Repackaging Lab Completed

Pharmaceutical Reformulation Lab Completed

FDA Registration Obtained

QPI and Nesvik Business Divisions Launched

Acquired 505(b)(2) Pre-IND Drug Assets

Filed Pre-IND’s on 505(b)(2) Pre-IND Drug Compounds

Commercialized FDA 361 Amniotic Tissue Platform Products

Expand Reformulation and Life Sciences Capabilities

Continue to Register Drug INDs

Establish Formal Clinical Trials

Expand Stem Cell R&D

 

2014

BioStem Technologies, Inc. Established

2016

Repackaging and Reformulation Facilities Built Out

Addition of Industry Experts and Key Business Advisors to Oversee Growth

2017

Repackaging Lab Completed

Pharmaceutical Reformulation Lab Completed

FDA Registration Obtained

2018

QPI and Nesvik Business Divisions Launched

Acquired 505(b)(2) Pre-IND Drug Assets

Filed Pre-IND’s on 505(b)(2) Pre-IND Drug Compounds

Commercialized FDA 361 Amniotic Tissue Platform Products

2019

Expand Reformulation and Life Sciences Capabilities

Continue to Register Drug INDs

Establish Formal Clinical Trials

Expand Stem Cell R&D

Growth Fueled by Conviction

From the day we were founded, BioStem Technologies has pursued a singular goal: growing into a biopharmaceutical company with the power to change lives for the better.

We began as a stem-cell company, driven by one of our founders’ experiences with the healing potential of this exciting – and evolving – branch of medicine. After being diagnosed with a rare form of cancer for the second time in 2011 and later beating it through chemotherapy and radiation, Henry (Chip) Van Vurst experienced partial paralysis and weakness. Through regenerative stem cell treatments, he was able to regain his quality of life.

Stem cell therapies may have been where we started, but our destination was always much broader. With the completion of our state-of-the-art API repackaging and pharmaceutical reformulation labs and finalization of our FDA registration in 2017, we were poised to become more than just pioneers in regenerative medicine.

BioStem soon grew into a fully-fledged, diversified biopharmaceutical company with quality and patient safety as our guiding principles. 2018 saw the launch of two more divisions: QPI, specializing in the repackaging of APIs, and Nesvik Pharmaceuticals, specializing in pharmaceutical reformulation. Thanks to these new additions, our stem-cell business took its place alongside the other divisions as BioStem Life Sciences.

With plans to further grow our portfolio to encompass 505(b)(2) drugs and more cell lines, begin clinical trials for products in the pipeline, and expand our reach internationally in the coming years, the stage is set for BioStem to become a leader in the production of high-quality, cutting-edge treatments that give patients more options—and more reasons to hope.

Discover What Drives Us

Explore Our Divisions